Gene Delivery Using Viral Vectors - Challenges in Delivery of Therapeutic Genomics and Proteomics - page 267

[186] Kwong AD, Frenkel N. Biology of herpes simplex virus (HSV) defective viruses and
development of the amplicon system. In: Kaplitt MG, Loewy AD, editors Viral vectors:
gene therapy and neuroscience applications. San Diego, CA: Academic Press; 1995.
p. 25-42.
[187] Roizman B, Sears AE. Herpes simplex viruses and their replication. In: Roizman B,
Whitley RJ, Lopez C, editors. The human herpesviruses. New York. NY: Raven Press;
1993. p. 11-68.
[188] Subramanian RP, Geraghty RJ. Herpes simplex virus type 1 mediates fusion through a
hemifusion intermediate by sequential activity of glycoproteins D, H, L, and B. Proc
Natl Acad Sci U.S.A. 2007;104:2903-8.
[189] Herold B. Glycoprotein C-independent binding of herpes simplex virus to cells requires
cell surface heparan sulfate and glycoprotein B. J Gen Virol 1994;75:1211-22.
[190] Tal-Singer R. Interaction of herpes simplex virus glycoprotein gC with mammalian cell
surface molecules. J Virol 1995;69:4471-83.
[191] Geraghty RJ, Claude H, Gary HC, Roselyn JE, Patricia GS. Entry of alpha herpes
viruses mediated by poliovirus receptor-related protein 1 and poliovirus receptor.
Science 1998;280:1618-20.
[192] Taddeo B, Roizman B. The virion host shutoff protein (UL41) of herpes simplex virus
1 is an endoribonuclease with substrate specificity similar to that of RNase A. J Virol
2006;80:9341-5.
[193] Skepper JN, Whiteley A, Browne H, Minson A. Herpes simplex virus nucleocapsids
mature to progeny virions by an envelopment→deenvelopment→reenvelopment path-
way. J Virol 2001;75:5697-702.
[194] Granzow H, Klupp BG, Fuchs W, Veits J, Osterrieder N, Mettenleiter TC. Egress of
alphaherpesviruses: comparative ultrastructural study. J Virol 2001;75:3675-84.
[195] Johnson PA, Wang MJ, Friedmann T. Improved cell survival by the reduction of imme-
diate-early gene expression in replication-defective mutants of herpes simplex virus
type 1 but not by mutation of the virion host shutoff function. J Virol 1994;68:6347-62.
[196] Glorioso JC, Goins WF, Meaney CA, Fink DJ, DeLuca NA. Gene transfer to brain
using herpes simplex virus vectors. Ann Neurol 1994;35:S28-34.
[197] Glorioso JC, DeLuca NA, Fink DJ. Development and application of herpes simplex
virus vectors for human gene therapy. Annu Rev Microbiol 1995;49:675-710.
[198] Smith RL, Geller AI, Escudero KW, Wilcox CL. Long-term expression in sensory neu-
rons in tissue culture from herpes simplex virus type1 (HSV-1) promoters in an HSV-1-
derived vector. J Virol 1995;69:4593-9.
[199] Geller A, Breakefield X. A defective HSV-1 vector expresses Escherichia coli- galacto-
sidase in cultured peripheral neurons. Science 1998;241:1667-9.
[200] Kramer MF, Coen DM. Quantification of transcripts from the ICP4 and thymidine
kinase genes in mouse ganglia latently infected with herpes simplex virus. J Virol
1995;69:1389-99.
[201] Samaniego LA, Neiderhiser L, DeLuca NA. Persistence and expression of the her-
pes simplex virus genome in the absence of immediate-early proteins. J Virol
1998;72:3307-20.
[202] Wu N, Watkins SC, Schaffer PA, DeLuca NA. Prolonged gene expression and cell sur-
vival after infection by a herpes simplex virus mutant defective in the immediate-early
genes encoding ICP4, ICP27, and ICP22. J Virol 1996;70:6358-68.
[203] Galanis E, Vile R, Russell SJ. Delivery systems intended for in vivo gene therapy of
cancer: targeting and replication competent viral vectors. Crit Rev Oncol Hematol
2001;38:177-92.